AbbVie Reports Financial Results for Third Quarter 2025
AbbVie released its financial results for the third quarter of 2025 on October 31. The company reported a diluted earnings per share (EPS) of $0.10 on a generally accepted accounting principles (GAAP) basis. This figure marks a decline of 88.6 percent compared to the same period last year. On an adjusted basis, diluted EPS stood at $1.86, down 38 percent. The results include an unfavorable impact of $1.50 per share related to acquired in-process research and development (IPR&D) and milestone expenses.
Revenue Overview
AbbVie reported net revenues of $15.776 billion for the quarter, representing a 9.1 percent increase on a reported basis and an 8.4 percent increase on an operational basis.
Performance by Portfolio
Immunology portfolio
The immunology segment generated global net revenues of $7.885 billion. This is an increase of 11.9 percent reported or 11.2 percent operational. Key products include:
- Skyrizi: $4.708 billion
- Rinvoq: $2.184 billion
- Humira: $993 million
Neuroscience portfolio
The neuroscience segment delivered $2.841 billion in global net revenues. This represents a 20.2 percent increase reported and 19.6 percent operational. Key products include:
- Vraylar: $934 million
- Botox Therapeutic: $985 million
- Combined Ubrelvy and Qulipta: $642 million
Oncology portfolio
The oncology segment reported $1.682 billion in global net revenues. This reflects a slight decline of 0.3 percent reported and 1.3 percent operational. Key products include:
- Imbruvica: $706 million
- Venclexta: $726 million
- Elahere: $170 million
Aesthetics portfolio
The aesthetics segment generated $1.193 billion in global net revenues. This is a decrease of 3.7 percent reported and 4.2 percent operational. Key products include:
- Botox Cosmetic: $637 million
- Juvederm: $253 million
Guidance Update
AbbVie raised its 2025 adjusted diluted EPS guidance range. Further details on the new guidance figures were not included in the release.
Summary
AbbVie posted growth in overall revenue for the third quarter despite a sharp decline in GAAP EPS. Growth in its immunology and neuroscience portfolios led overall revenue gains, while oncology and aesthetics revenues showed small declines. The results include one-time charges related to acquired research and development. The company raised its EPS guidance for the full year 2025.
#internationalfinancialnews #latestmarketregulations #globalfinancialupdates #financialnews2025 #internationalmarkettips #financialnews #economicheadlines #interestrateupdates #stockmarketalerts #bankfailurenews #inflationpolicychanges #cryptonewsupdates #centralbankannouncements #taxreformdelays #federalbudgetrequirements #marketsafetynews #investmenttrend2025 #economicforecastalerts #globaleconomicnews #newtradingbans #marketreopeningnews #beststocks2025 #financialinsurancenews #regulationguidelinechanges #bankstrikeupdates #globaleconomicdisruptions #breakingfinancialnews #notedmarketsectors #financialforecast2025 #newinvestmentroutes #globalfinancerules #safestplacestoinvest #financeindustrynews #investmentbanupdates #internationaltaxupdates #financebubblealerts #financialboardupdates #realtimemarketadvisories #policychanges2025 #embassyfinancealerts #latestfinancenews #livingmediterranean #retirementfinanceguide #retirementplanningnews #retirementinvestmenttips #globalretirementtrends #earlyretirementnews #retirementtaxstrategies #bestcountriesforretirement #retirementaccountupdates #retirementbudgeting #retirementfundingalerts #internationalretirementnews
